Rarely has an IPO sparked so much interest and speculation as the upcoming IPO for Livongo. Yet with all this speculation there seems to be a general agreement that the Livongo business model is not sustainable over the long haul. This is not just because there is an intense amount of competition in the digital diabetes space which will create pricing pressure. Rather over just what is Livongo selling.
Before we throw in our two cents let’s review just what Livongo and the others in digital diabetes say they do. The concept of digital diabetes as we have noted . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.